Picture loading failed.

Anti-CD3E therapeutic antibody (Pre-made Tebentafusp biosimilar,scFv Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The drug, tebentafusp, is a type of treatment called a bispecific fusion protein. It works by helping immune cells get close enough to cancer cells to attack them. The clinical trial evaluated the drug as an initial treatment for people with metastatic uveal melanoma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-555-1mg 1mg 3090
GMP-Bios-ab-555-10mg 10mg 21890
GMP-Bios-ab-555-100mg 100mg 148000
GMP-Bios-ab-555-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD3E therapeutic antibody (Pre-made Tebentafusp biosimilar,scFv Fusion)
INN Name Tebentafusp
FormatscFv Fusion
Species ReactivityHuman
CH1 Isotypena
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
Conditions Approvedna
Conditions ActiveMalignant melanoma;Uveal melanoma
Conditions Discontinuedna
Development Techna